Valion Bio, Inc. · NASDAQ:VBIO
Valion Bio — Tivic Health Systems — Investor Presentation (October 2022)
22 slides from Valion Bio's investor presentation, Oct 26, 2022
Slide 1: Nasdaq Investor Presentation, October 2022
Exhibit 99.1 Make text into real text. Use vector graphic for logo. 72? Or 150? The future of medicine is electronic. N A S D A Q I N V E S T O R P R E S E N T A T I O N N A S D A Q I N V E S T O R P R E S E N T A T I O N T I V C 2 0 2 2 S E P T T I V C 2 0 2 2 O C T O B E R
Slide 2: Forward Looking Statements
F O R W A R D L O O K I N G S T A T E M E N T S This presentationcontains forward-looking statements. All statements other than statements of historical facts contained inthis presentationmay be forward-looking statements. Statementsregarding our future results of operations and financial position,
Slide 3: The Big Idea
T H E B I G I D E A The body is an electrochemical system. Bioelectronic medicine restores health by tuning body’s electrical signals. Bioelectronic medicine has the “potential to become a pillar of medical treatment.” Bioelectronics ‘jump-start the next wave of device therapeutics. October 2019 3
Slide 4: Bioelectronics Trajectory: Moving from Implants to Non-invasive
B I O E L E C T R O N I C S T R A J E C T O R Y Moving from Implants to Non-invasive IMPLANTS NON-INVASIVE 1960s 1990s 2010s 2020s Pacemakers Deep Brain, Sleep Apnea Non-Invasive Spinal Cord Bioelectronics • Bioelectronics historically required implanted technology. • Tivic Health has delivered ways
Slide 5: Clears Congestion, Stops Pain
C L E A R S C O N G E S T I O N , S T O P S P A I N 99 $ 169 • Pulsed current flows from tip through sinuses MSRP • 5 minutes, 2x per day Sinus Relief R&D PRODUCT PIPELINE T I V I C H E A L T H . C O M 5 NASDAQ: TIVC
Slide 6: Handheld Platform for Non-invasive Peripheral Nerve Stimulation
H A N D H E L D P L A T F O R M FOR Non-invasive Peripheral Nerve Stimulation Proprietary Programmable Patented Algorithms Parameters Form Factor % Peripheral nerve stimulation market forecast to grow at CAGR. 35 ~ IDTechEx. Bioelectronic Medicine 2019-2029. T I V I C H E A L T H . C O M 6 NASDAQ: T
Slide 7: From IPO November 2021: A Year of Upwards Momentum
F R O M I P O N O V E M B E R 2 0 2 1 2022: A Year of Upwards Momentum Post-operative Pain • Clinical program in progress Migraine • Commercial evaluation complete • Clinical program in development M&A / Licensing • Reliefband acquisition agreement signed T I V I C H E A L T H . C O M 7 NASDAQ: TIVC
Slide 8: Expanding Our Product Offerings
Expanding Our On October 7, 2022, Tivic entered a definitive agreement for the purchase of the Reliefband product line for the treatment of nausea and retching. Product Offerings 99 99 99 99 $ $ $ $ 279 239 139 99 MSRP MSRP MSRP MSRP Similar version sold Rx as Reletex P R O D U C T L I N E T I V I C
Slide 9: Both Rooted in Strong Foundations
F O U N D A T I O N S Both Rooted in Strong Foundations Sinus Pain, Pressure, Congestion Nausea and Vomiting Products in Market 1 OTC 4 OTC & 1 Rx FDA & CE Mark Indications 3 7 Issued Patents 5 5 Patents Pending 18 1 Registered Trademarks 9 13 Peer-Reviewed Publications 2 40 Reimbursed - YES T I V I
Slide 10: Parallel and Complementary Sales Channels
T R I E D & T R U E A P P R O A C H Parallel and Complementary Sales Channels direct-to-consumer . . company website . . . . . . .com . . . . T I V I C H E A L T H . C O M 10 NASDAQ: TIVC
Slide 11: Similar Mechanisms of Action
B A S E D O N N E U R O M O D U L A T I O N S C I E N C E Similar Mechanisms of Action Trigeminal nerve mediates Median nerve pain relief disrupts nausea signals in brain stem Sympathetic nerve induces vasoconstriction Vagus nerve restores normal gastric functioning and prevents vomiting T I V I C H
Slide 12: H . C O M H . C O M NASDAQ: TNIASVDC AQ:
T I V I C H E A L T H . C O M T I V I C H E A L T H . C O M 12 NASDAQ: TNIASVDC AQ: TIVC
Slide 13: H . C O M
T I V I C H E A L T H . C O M 13 NASDAQ: TIVC
Slide 14: ClearUP & Reliefband Sales Revenue History
C L E A R U P & R E L I E F B A N D * unaudited Sales Revenue History $10.0 $20.0 $9.0 $18.0 $8.0 $16.0 14.3 $ 11.1B $7.0 $14.0 US Segment Over-the-counter $6.0 $12.0 Sinus Care $ $5.0 $10.0 2.4B US Segment 7.5 $4.0 $8.0 Over-the-counter Nausea Care $3.0 $6.0 4.3 $2.0 $4.0 1.3 2.5 1.8 1.8 0.9 $1.0 $
Slide 15: Structured Approach to Growth
M A R K E T D E V E L O P M E N T Structured Approach to Growth 2016 – 2019 2020 – 2021 2022 2023 2024 – 2026 New indications Reliefband Product Build credibility Harden integration development and grow New product platforms ecommerce FDA clearance Healthcare Staged international practitioner market
Slide 16: Financials: Tivic Operations Results
F I N A N C I A L S Tivic Operations Results Twelve Months Six Months High growth momentum in Ended December 31 Ended June 30 revenue FY 2021 FY 2020 Interim 2022 Interim 2021 (in thousands) • 36% YOY revenue growth in FY 2021 Revenues $ 1,166 $ 860 $ 956 $ 591 • 62% YOY revenue growth in Q2 2022 Gr
Slide 17: Financials: Tivic Financial Position
F I N A N C I A L S Tivic Financial Position (in thousands) June 30, 2022 Cash and Cash Equivalents $ 9,049 Total Assets 11,026 Total Liabilities 2,839 Total Stockholders’ Equity $ 11,026 • Simple balance sheet • No debt T I V I C H E A L T H . C O M 17 NASDAQ: TIVC
Slide 18: Financials: Cap Table
F I N A N C I A L S Cap Table October 5, 2022 Common Stock 9,679,295 Options (WAEP: $2.00) 1,268,850 Warrants (WAEP: $4.34) 272,680 Fully Diluted Shares 11,220,825 • Single class of shares T I V I C H E A L T H . C O M 18 NASDAQ: TIVC
Slide 19: Leadership Team
L E A D E R S H I P T E A M Experienced, Execution-oriented Leadership Veronica Cai Blake Gurfein Ryan Sabia Sanjay Ahuja Jennifer Ernst Chief Financial Officer, Chief Scientific Officer, Chief Operations Officer SVP, Quality & Chief Executive Officer, MBA CPA Ph.D. Regulatory Affairs Global sales,
Slide 20: Highlights: Investor Summary
H I G H L I G H T S Investor Summary FDA-cleared products in high-growth sector. Large available markets - $13.5B combined US markets. Established Tier 1 channels growing. Regulatory clearances for both US and international sales. Robust IP portfolio, recently issued patents. Clinical validation wit
Slide 21: Jennifer Ernst, CEO, Tivic Health
Jennifer Ernst CEO, Tivic Health i r @ t i v i c h e a l t h . c o m T I V I C H E A L T H . C O M NASDAQ: TIVC
Slide 22: Appendix: Similar Mechanisms of Action
APPENDIX S I M I L A R M E C H A N I S M S O F A C T I O N 1. Maul, Ximena A., et al. Microcurrent 1. Guo ZL, Malik S. Acupuncture activates a technology for rapid relief of sinus pain: a direct pathway from the nucleus tractus randomized, placebo‐controlled, solitarii to the rostral ventrolateral m
Tivic Health Systems — Investor Presentation (October 2022) on 6ix